Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group
暂无分享,去创建一个
S. Kimura | Y. Kanda | H. Minamiguchi | I. Matsumura | Y. Miyazaki | H. Kiyoi | N. Hosono | H. Kato | H. Handa | N. Hiramoto | T. Ono | H. Fujita | Tsutomu Takahashi
[1] Dustin L. Stwalley,et al. Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. , 2019, The Lancet. Infectious diseases.
[2] A. Butler,et al. Antimicrobial Stewardship in a Hematological Malignancy Unit: Carbapenem Reduction and Decreased Vancomycin-Resistant Enterococcus Infection. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] H. Fukuda,et al. Eight-Year Experience of Antimicrobial Stewardship Program and the Trend of Carbapenem Use at a Tertiary Acute-Care Hospital in Japan—The Impact of Postprescription Review and Feedback , 2019, Open forum infectious diseases.
[4] P. Ljungman,et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). , 2019, The Lancet. Infectious diseases.
[5] S. Kutsuna,et al. The impact of infectious disease consultation in candidemia in a tertiary care hospital in Japan over 12 years , 2019, PloS one.
[6] M. Murad,et al. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis , 2019, BMJ Supportive & Palliative Care.
[7] G. Maschmeyer,et al. Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation , 2019, Expert review of anti-infective therapy.
[8] J. M. Rodriguez,et al. Impact of Infectious Disease Consultation on Clinical Management and Mortality in Patients With Candidemia. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] R. Humphries,et al. Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] M. Venditti,et al. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome , 2018, European Journal of Clinical Microbiology & Infectious Diseases.
[11] T. Naoe,et al. Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001–2005 using the Japan Adult Leukemia Study Group AML201 protocols , 2018, Supportive Care in Cancer.
[12] G. Guillerm,et al. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study , 2018, Infectious diseases.
[13] P. Bruzzi,et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. , 2018, The Journal of infection.
[14] T. Naoe,et al. Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group , 2017, Supportive Care in Cancer.
[15] C. Heussel,et al. Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis , 2017, European Radiology.
[16] M. Paul,et al. Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[17] D. Denning,et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] K. Iwata,et al. Is de-escalation of antimicrobials effective? A systematic review and meta-analysis. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[19] Matthew H Samore,et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] J. Sobel,et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] J. Sobel,et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Y. Kanda,et al. Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[23] G. Tomlinson,et al. Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] J. Wingard,et al. Combination Antifungal Therapy for Invasive Aspergillosis , 2015, Annals of Internal Medicine.
[25] E. Anaissie,et al. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. , 2014, Blood.
[26] D. Livermore,et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia , 2013, Haematologica.
[27] K. Sepkowitz,et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] S. Ichiyama,et al. Close cooperation between infectious disease physicians and attending physicians can result in better management and outcome for patients with Staphylococcus aureus bacteraemia. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] T. Naoe,et al. Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group , 2009, International journal of hematology.
[30] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[32] R. Foà,et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. , 2005, The New England journal of medicine.
[33] L. Leibovici,et al. Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.
[34] R. Ohno,et al. Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.